Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Endava plc Lawsuit

Endava shares fell about 79%, from $10.18 to $2.11 during the stated class period, including a 24.37% one-day decline after the company disclosed its CFO was on administrative leave pending an Audit Committee investigation into accounting for certain customer and supplier agreements. The lawsuit alleges investors were not told that the accounting required additional review, that FY2026 results would be delayed, or that internal controls were in doubt. Q1 FY2026 revenue was £178.2 million, down 8.6% year over year; Q3 included a £364.6 million goodwill write-down, a £23.2 million deferred tax charge, and a £372.0 million loss before tax. These are allegations in a pending securities class action; the lead-plaintiff deadline is November 30, 2026.

Analysis

The key risk is not the already-recognized goodwill write-down; it is whether the agreement review changes reported revenue, contract economics, or the reliability of prior-period numbers. If customers or suppliers can alter contract terms, the record-booking narrative may have overstated how much backlog could convert into revenue and cash. That would weaken confidence in forward growth as well as reported controls. The lawsuit’s claims remain allegations, and the noncash impairment alone does not establish a comparable cash or operating loss.

Near term, the CFO leave and delayed results create an information vacuum and potential volatility; the November 30 lead-plaintiff deadline is a procedural headline, not a fundamental catalyst. Over 1–3 months, the decisive evidence is the audit committee’s findings and whether FY2026 reporting requires revisions or further delay. Over 6–18 months, client retention and bookings-to-revenue conversion will determine whether this is a control event layered on cyclical weakness or a more durable deterioration. If execution falters, clients may shift incremental work to larger providers such as Accenture, Cognizant, or EPAM, though that substitution is unlikely to be immediate.

Contrarian risk/reward is asymmetric but not automatically attractive for a fresh outright short: after a severe repricing, clean audited accounts or a limited-scope issue could trigger a sharp relief rally, while uncertainty makes valuation anchors unreliable. Verify the scope of agreements under review, any restatement, cash conversion, and revised guidance before treating the booking shortfall as structural.

Key Decisions for Investors

• Keep DAVA on a high-risk watchlist; do not add to a long position until the company publishes the audit committee’s conclusions and reliable FY2026 financials. The current evidence does not establish the size of any accounting adjustment.
• If the investigation confirms material reporting/control problems or results are delayed again, consider a defined-risk relative-value short in DAVA versus a diversified IT-services peer basket; size for gap and squeeze risk, and avoid an unhedged short solely on the lawsuit announcement.
• Use audited revenue, operating cash flow, and bookings-to-revenue conversion as confirmation points. A clean filing with no material revisions and stable client demand would falsify the deeper-deterioration thesis and could drive a relief rebound.
• Treat the class-action deadline as a sentiment/volatility watch item, not a standalone trading catalyst; litigation allegations are not findings of liability.